Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

264
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
264
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Guideline (EuroGuiDerm) on atopic eczema: Living update.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

First update of the living European guideline (EuroGuiDerm) on atopic eczema.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Related Experiment Video

Updated: May 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

[Personalised medicine. Aims and challenges].

T Bieber1, K Broich

  • 1Klinik und Poliklinik für Dermatologie und Allergologie, Universitäts-Klinikum Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Deutschland, Thomas.Bieber@ukb.uni-bonn.de.

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|October 31, 2013
PubMed
Summary

Personalised medicine uses biomarkers to tailor treatments for individuals, improving drug efficacy and safety. This proactive approach shifts healthcare from reactive to preventive, enhancing patient outcomes and potentially reducing costs.

More Related Videos

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.6K

Related Experiment Videos

Last Updated: May 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.6K

Area of Science:

  • Biomedical Sciences
  • Pharmacogenomics
  • Clinical Medicine

Context:

  • Increasing complexity of diseases necessitates novel therapeutic strategies.
  • Current healthcare models are often reactive, costly, and inefficient.
  • Growing emphasis on patient participation and health literacy.

Purpose:

  • To develop tailored therapeutic strategies for individuals and patient subgroups.
  • To improve the efficacy and safety of medicinal products through personalization.
  • To enable early identification of at-risk populations for chronic diseases.

Summary:

  • Personalised medicine leverages biomarker-based approaches to address disease complexity.
  • It aims to create more adapted treatments, enhancing drug efficacy and safety.
  • This approach facilitates the identification of at-risk populations and early interventions.

Impact:

  • Facilitates a shift towards a more cost-effective, targeted, and preventive healthcare system.
  • Enables a proactive healthcare model, termed 'P4 medicine' (Predictive, Preventive, Personalised, Participative).
  • Improves patient outcomes by providing treatments suited to individual genetic and clinical profiles.